Dublin, May 09, 2023 (GLOBE NEWSWIRE) -- The "Global Thyroid Cancer Drugs Market by Drug (Cabozantinib-S-Malate, Caprelsa, Cometriq), End User (Hospitals, Oncology Clinics, Research Organizations) - Cumulative Impact of High Inflation - Forecast 2023-2030" report has been added to ResearchAndMarkets.com's offering.
The Global Thyroid Cancer Drugs Market size was estimated at USD 620.63 million in 2022, USD 685.14 million in 2023, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 10.53% to reach USD 1,382.70 million by 2030.
Market Dynamics
Drivers
- Growing Prevalence of Thyroid Cancer Cases Across the Globe
- Increasing Focus on Early Diagnosis and Treatment
- Private Organizations Increasing Cancer Screening Programs
Restraints
- Dearth of Skilled Workers and Standardization of the Procedure
Opportunities
- Favorable Government Initiatives Promoting Cancer Awareness and Introduction of Reimbursement Policies
- Ongoing Advancements in Treatment Procedures With Improved Quality
Challenges
- Stringent Government Drug Approval Procedures
Market Segmentation & Coverage:
- Based on Drug, market is studied across Cabozantinib-S-Malate, Caprelsa, Cometriq, Doxorubicin Hydrochloride, Ipilimumab, Lenvatinib Mesylate, Nivolumab, and Vandetanib. The Lenvatinib Mesylate is projected to witness significant market share during forecast period.
- Based on End User, market is studied across Hospitals, Oncology Clinics, and Research Organizations. The Hospitals is projected to witness significant market share during forecast period.
- Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.74% in 2022, followed by Europe, Middle East & Africa.
Market Statistics:
The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix is essential for assessing the Global Thyroid Cancer Drugs Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).
Market Share Analysis:
The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.
The report answers questions such as:
- What is the market size and forecast of the Global Thyroid Cancer Drugs Market?
- What are the inhibiting factors and impact of COVID-19 shaping the Global Thyroid Cancer Drugs Market during the forecast period?
- Which are the products/segments/applications/areas to invest in over the forecast period in the Global Thyroid Cancer Drugs Market?
- What is the competitive strategic window for opportunities in the Global Thyroid Cancer Drugs Market?
- What are the technology trends and regulatory frameworks in the Global Thyroid Cancer Drugs Market?
- What is the market share of the leading vendors in the Global Thyroid Cancer Drugs Market?
- What modes and strategic moves are considered suitable for entering the Global Thyroid Cancer Drugs Market?
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 251 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value (USD) in 2022 | $620.63 Million |
| Forecasted Market Value (USD) by 2030 | $1382.7 Million |
| Compound Annual Growth Rate | 10.5% |
| Regions Covered | Global |
Key Topics Covered:
1. Preface
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
6. Thyroid Cancer Drugs Market, by Drug
7. Thyroid Cancer Drugs Market, by End User
8. Americas Thyroid Cancer Drugs Market
9. Asia-Pacific Thyroid Cancer Drugs Market
10. Europe, Middle East & Africa Thyroid Cancer Drugs Market
11. Competitive Landscape
12. Company Usability Profiles
13. Appendix
Companies Mentioned
- AstraZeneca PLC
- Bayer AG
- Biovista Inc.
- Bristol Myers Squibb
- Eisai Co., Ltd.
- Eli Lilly and Company
- Exelixis Inc.
- GlaxoSmithKline PLC
- Lupin Limited
- Merck & Co., Inc
- Mylan N.V.
- Novartis AG
- Sanofi S.A.
- Teva Pharmaceutical Industries Ltd
- Vascular Biogenics Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/bpw7gq
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
